The Struggles of India’s Vaccine Giant

The Daily

The New York Times

Daily News, News

4.4 • 102.8K Ratings

🗓️ 24 June 2021

⏱️ 28 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. What has that meant for the nations promised millions of doses? Guest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi.

Transcript

Click on a timestamp to play from that location

0:00.0	From New York Times, I'm Michael Borrow.
0:02.8	This is Bailey.
0:04.0	MUSIC
0:10.2	Today.
0:12.2	With plenty of vaccine available,
0:14.2	COVID is now in retreat in North America and also in Europe,
0:18.6	but not so in the global south.
0:20.8	And there is...
0:21.6	While the United States has vaccinated almost half its population
0:25.6	and begun to fully reopen...
0:27.6	Nepal is experiencing a devastating wave of COVID-19.
0:31.4	Bangladesh is also dealing with a rise in coronavirus.
0:34.0	Dozens of countries are lagging far behind.
0:37.2	In South Africa, for example, only 1% of the population
0:41.1	has had their first jab.
0:42.6	It turns out a big reason why is that they were all counting
0:46.8	on a single vaccine maker in India.
0:49.7	There are many people here in India who believe that the
0:52.7	Syrim Institute and the government
0:54.8	over-promise when it came to those commitments for vaccines.
0:58.7	I mean, you know, that's how we...
1:00.4	Kevin Rus spoke with our colleague, Emily Schmaw,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The New York Times, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The New York Times and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.